BDBM307547 BDBM307549::N-(2-(1,2,4-oxadiazol-3-yl)propan-2-yl)-5-(6-ethoxy-2-(4-fluorophenyl)-3-(methylcarbamoyl)benzofuran-5-yl)-2-methoxynicotinamide::US10150747, Example 14
SMILES: CCOc1cc2oc(c(C(=O)NC)c2cc1-c1cnc(OC)c(c1)C(=O)NC(C)(C)c1ncon1)-c1ccc(F)cc1
InChI Key: InChIKey=LYWYJLCYHLNQJU-UHFFFAOYSA-N
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RNA polymerase (NS5B) (Hepatitis C virus (HCV)) | BDBM307547 (BDBM307549 | N-(2-(1,2,4-oxadiazol-3-yl)propan-2-y...) | PDB UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.52 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company US Patent | Assay Description To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with... | US Patent US10150747 (2018) BindingDB Entry DOI: 10.7270/Q2H70HWJ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RNA polymerase (NS5B) (Hepatitis C virus (HCV)) | BDBM307547 (BDBM307549 | N-(2-(1,2,4-oxadiazol-3-yl)propan-2-y...) | PDB UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 2.95 | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company US Patent | Assay Description To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with... | US Patent US10150747 (2018) BindingDB Entry DOI: 10.7270/Q2H70HWJ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RNA polymerase (NS5B) (Hepatitis C virus (HCV)) | BDBM307547 (BDBM307549 | N-(2-(1,2,4-oxadiazol-3-yl)propan-2-y...) | PDB UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.73 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company US Patent | Assay Description To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with... | US Patent US10150747 (2018) BindingDB Entry DOI: 10.7270/Q2H70HWJ | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
RNA polymerase (NS5B) (Hepatitis C virus (HCV)) | BDBM307547 (BDBM307549 | N-(2-(1,2,4-oxadiazol-3-yl)propan-2-y...) | PDB UniProtKB/SwissProt B.MOAD DrugBank GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | n/a | n/a | 3.20 | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Company US Patent | Assay Description To evaluate compound efficacy, titrated compounds were transferred to sterile 384-well tissue culture treated plates, and the plates were seeded with... | US Patent US10150747 (2018) BindingDB Entry DOI: 10.7270/Q2H70HWJ | |||||||||||
More data for this Ligand-Target Pair |